SRRT and melanoma: To generate an antigen-specific system to test the contribution of ARS2 to CD8+ T-cell-mediated antitumor immunity in vivo, ARS2iKO mice were crossed with PMEL TCR transgenic mice to generate ARS2iKO CD8+ T cells that recognize the gp10025–33 antigen presented by H2-Db on B16 melanoma cells [30].